Viagra Research Today is a free monthly online journal that collates and summarizes the latest research about Viagra, including details on sildenafil, erectile dysfunction, impotence, side-effects, alternatives.

Volume 3 (2006), Issue 8 (August)

1. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
   BJU Int, 98(2): 414-23. [Abstract] [Full-text]
2. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
   BJU Int, 98(2): 259-72. [Abstract] [Full-text]
3. Phosphodiesterase Inhibitors in Raynaud's Phenomenon.
   Ann Pharmacother, 40(7): 1388-93. [Abstract] [Full-text]
4. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
   Nat Rev Drug Discov, 5(8): 689-702. [Abstract] [Full-text]
5. Phosphodiesterases in the CNS: targets for drug development.
   Nat Rev Drug Discov, 5(8): 660-70. [Abstract] [Full-text]
6. Effect of sildenafil on arterial stiffness, as assessed by pulse wave velocity, in patients with erectile dysfunction.
   Int J Urol, 13(7): 956-9. [Abstract] [Full-text]
7. Male erectile dysfunction following spinal cord injury: a systematic review.
   Spinal Cord, 44(8): 465-73. [Abstract] [Full-text]
8. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
   Int J Pharm, 320(1): 64-70. [Abstract] [Full-text]
9. Dipyridamole may induce migraine in patients with migraine without aura.
   Cephalalgia, 26(8): 925-33. [Abstract] [Full-text]
10. Phosphodiesterase-5 isoforms: differential cyclic guanyl monophosphate binding and cyclic guanyl monophosphate catalytic activities, and inhibitory effects of sildenafil and vardenafil.
    J Urol, 176(3): 1242-7. [Abstract] [Full-text]
11. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Int J Clin Pract, 60(8): 967-75. [Abstract] [Full-text]
12. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.
    Urology, 68(2): 397-401. [Abstract] [Full-text]
13. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment.
    Diabet Med, 23(8): 873-8. [Abstract] [Full-text]
14. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    J Med Chem, 49(17): 5363-71. [Abstract] [Full-text]
15. Erectile dysfunction and viagra use: what's up with college-age males?
    J Adolesc Health, 39(3): 452-4. [Abstract] [Full-text]
16. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Eur J Clin Invest, 36: 32-8. [Abstract] [Full-text]
17. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    BJU Int, 98(3): 623-9. [Abstract] [Full-text]
18. Sildenafil for pulmonary arterial hypertension: when blue turns into white.
    Expert Opin Pharmacother, 7(13): 1801-10. [Abstract] [Full-text]
19. Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
    Am J Hypertens, 19(9): 915-9. [Abstract] [Full-text]
20. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    J Sex Med, 3(5): 901-9. [Abstract] [Full-text]

© 2004-2008 Viagra Research Today. All Rights Reserved.